

(Shimadzu Corporation, Japan) using a gradient of 0.1 % TFA in acetonitrile and water. The eluted fractions were reanalyzed on Analytical HPLC system (Shimadzu Corporation, Japan) using a C18 LICHROSPHERG®, WP-300 (300 X 4) (reverse phase C18 column) reverse- phase column. Acetonitrile was evaporated and the fractions were lyophilized to obtain the pure peptide. The identity of each peptide was confirmed by electron-spray mass spectroscopy.

In the Claims

Please cancel claims 15-20.

REMARKS

Claims 1-14 are being examined in this application. Claims 15-20 have been cancelled. Applicants preserve all rights to file one or more divisional applications directed to the subject matter of claims 15-20.

Page 11 of the specification has been amended to include "reverse phase C18 column" after LICHROART C,8 and C18 LICHROSPHERE , WP-300.

The Examiner has rejected Claims 1-14 under 35 USC 112, first paragraph. Applicants respectfully traverse this rejection.

The compounds of SEQ ID NO: 3-12 were extensively tested for anticancer activity on a large number of human tumor cell lines and were established to have a broad spectrum of activity comprising major cancer types. SEQ ID NO:3 was tested on 10 different human tumor cell lines representing 8 different cancers, namely, breast, pancreas, stomach, oral, lung, colon, ovary and leukemia, while compounds SEQ ID NO: 4-8 were tested on 8 different human tumor cell lines